

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4302939

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	4

CONVEYING PARTY DATA

Name	Execution Date
NOVARTIS AG	05/23/2016

RECEIVING PARTY DATA

Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15240385

CORRESPONDENCE DATA**Fax Number:** (415)268-7522*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 415-268-6846**Email:** mstout@mofo.com**Correspondent Name:** OTIS LITTLEFIELD**Address Line 1:** MORRISON & FOERSTER LLP**Address Line 2:** 425 MARKET STREET**Address Line 4:** SAN FRANCISCO, CALIFORNIA 94105-2482

ATTORNEY DOCKET NUMBER:	303822006710
NAME OF SUBMITTER:	OTIS LITTLEFIELD
SIGNATURE:	/Otis Littlefield/
DATE SIGNED:	03/03/2017

Total Attachments: 3

source=4-Assignment-Novartis_AG_to_GSK-30382-2006710#page1.tif

source=4-Assignment-Novartis_AG_to_GSK-30382-2006710#page2.tif

source=4-Assignment-Novartis_AG_to_GSK-30382-2006710#page3.tif


CONFIRMATORY ASSIGNMENT


WE, **NOVARTIS AG** a company limited by shares duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby declare that we are the sole owner of the following patents/ patent applications as listed on Appendix A entitled "INJECTABLE VACCINES AGAINST MULTIPLE MENINGOCOCCAL SEROGROUPS".

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS AG** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium


Dated this 23 day of May 2016

Signed for and on behalf of
NOVARTIS AG


Edward R. Djahni
Authorized Signatory on behalf of
NOVARTIS AG


Christine B. Ling
Authorized Signatory on behalf of
NOVARTIS AG

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA


Theodore R. Furman
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA

APPENDIX A

Country	Application Date	Application Number	Grant Date	Patent Number
Austria	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Austria	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Belgium	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Belgium	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Canada	30-Jan-04	2514328		
China	30-Jan-04	200480008275 4	07-Apr-10	ZL200480008275 4
China	30-Jan-04	201010119485 8		
China	30-Jan-04	201010119484 3	18-Jun-14	ZL201010119484 3
China	30-Jan-04	201010118498 3	04-Jun-14	ZL201010118498 3
Czech Republic	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Czech Republic	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Denmark	30-Jan-04	04708762 4	11-Apr-12	EP1587537
EP	15-Dec-09	09075549 7	05-Mar-14	EP2191844
EP	15-Dec-09	09075550 5	03-Apr-13	EP2172213
EP	26-Sep-10	10179776 9		
EP	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Finland	15-Dec-09	09075549 7	05-Mar-14	EP2191844
Finland	30-Jan-04	04708762 4	11-Apr-12	EP1587537
France	30-Jan-04	04708762 4	11-Apr-12	EP1587537
France	15-Dec-09	09075549 7	05-Mar-14	EP2191844
France	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Great Britain	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Great Britain	15-Dec-09	09075549 7	05-Mar-14	EP2191844
Great Britain	30-Jan-03	0302217 5		
Great Britain	13-Mar-03	0305831 0		
Great Britain	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Great Britain	02-Oct-03	0323101 6		
Germany	30-Jan-04	04708762 4	11-Apr-12	602004037277 3
Germany	15-Dec-09	09075549 7	05-Mar-14	602004044550 9
Germany	15-Dec-09	09075550 5	03-Apr-13	602004041618 5
Greece	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Greece	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Hong Kong	09-Sep-10	10108541 5	10-Jan-14	HK1141999
Hungary	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Hungary	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Ireland	30-Jan-04	04708762 4	11-Apr-12	EP1587537
Ireland	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Italy	15-Dec-09	502014902259198	05-Mar-14	EP2191844
Italy	15-Dec-09	502013902159950	03-Apr-13	EP2172213
Italy	30-Jan-04	502012902063156	11-Apr-12	EP1587537
Japan	15-Sep-10	2010-207341		
Japan	05-Sep-13	2013-183664		
Japan	30-Jan-04	2006-502485	22-Sep-11	4827726

VN51926

Japan	24-Aug-15	2015-164950		
Luxembourg	30-Jan-04	04706762 4	11-Apr-12	EP1587537
Netherlands	30-Jan-04	04706762 4	11-Apr-12	EP1587537
Netherlands	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Netherlands	15-Dec-09	09075549 7	05-Mar-14	EP2191844
WO	30-Jan-04	PCT/IB2004/000651		
Portugal	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Portugal	30-Jan-04	04706762 4	11-Apr-12	EP1587537
Portugal	15-Dec-09	09075549 7	05-Mar-14	EP2191844
Switzerland	03-Sep-14	C02191844/01	28-Aug-15	C2191844/01
Switzerland	15-Dec-09	09075549 7	05-Mar-14	EP2191844
Switzerland	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Switzerland	30-Jan-04	04706762 4	11-Apr-12	EP1587537
Spain	30-Jan-04	04706762 4	11-Apr-12	EP1587537
Spain	15-Dec-09	09075550 5	03-Apr-13	EP2172213
Spain	15-Dec-09	09075549 7	05-Mar-14	EP2191844
Sweden	15-Dec-09	09075549 7	05-Mar-14	EP2191844
Sweden	30-Jan-04	04706762 4	11-Apr-12	EP1587537
Turkey	30-Jan-04	2012/07671	11-Apr-12	TR201207671
Turkey	15-Dec-09	2014/04192	05-Mar-14	EP2191844
Turkey	15-Dec-09	2013/04749	03-Apr-13	EP2172213
United States	30-Jan-04	10/543455		